Bob Lwenberg

List of Publications by Year in Descending Order

137 papers	15,877 citations	47 h-index	126 g-index
145 ext. papers	19,274 ext. citations	7.3 avg, IF	5.93 L-index

#	Paper	IF	Citations
137	MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME.. *Blood*, **2022**,	2.2	14
136	Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation. *Blood*, **2021**, 138, 1276-1276	2.2	0
135	Towards precision medicine for AML. *Nature Reviews Clinical Oncology*, **2021**, 18, 577-590	19.4	21
134	Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. *Molecular Oncology*, **2021**, 15, 2285-2299	7.9	0
133	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. *Blood*, **2021**, 137, 1792-1803	2.2	51
132	RUNX1 germline variants in RUNX1-mutant AML: how frequent?. *Blood*, **2021**, 137, 1428-1431	2.2	5
131	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood*, **2021**, 137, 751-762	2.2	77
130	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. *Cancers*, **2021**, 13,	6.6	2
129	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. *Blood Advances*, **2021**, 5, 1110-1121	7.8	9
128	PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse. *Leukemia*, **2021**, 35, 2693-2697	10.7	0
127	Professor Anton Hagenbeek 1948-2021: Father of MRD and lymphoma expert. *Bone Marrow Transplantation*, **2021**, 56, 2038-2039	4.4	
126	DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia. *Blood Advances*, **2021**, 5, 4476-4479	7.8	1
125	The long road: improving outcome in elderly "unfit" AML?. *Blood*, **2020**, 135, 2114-2115	2.2	1
124	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. *Science Translational Medicine*, **2020**, 12,	17.5	50
123	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. *Scientific Reports*, **2020**, 10, 10315	4.9	3
122	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123□CD3 Bispecific Dart□ Molecule, in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 26-28	2.2	1
121	TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 3-4	2.2	

120	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. *Blood*, **2020**, 136, 16-18	2.2	7
119	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. *Blood*, **2020**, 136, 19-21	2.2	2
118	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. *European Journal of Haematology*, **2020**, 104, 162-169	3.8	2
117	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. *Blood Advances*, **2020**, 4, 5011-5024	7.8	41
116	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. *Cancers*, **2020**, 12,	6.6	3
115	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. *Blood Advances*, **2020**, 4, 4267-4277	7.8	4
114	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Blood*, **2019**, 133, 1630-1643	2.2	219
113	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. *Blood*, **2019**, 134, 951-959	2.2	16
112	Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 CD3 Bispecific Dart Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2019**, 134, 460-460	2.2	2
111	Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. *Blood*, **2019**, 134, 733-733	2.2	11
110	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart Molecule for T-Cell Redirected Therapy. *Blood*, **2019**, 134, 5144-5144	2.2	3
109	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. *Blood*, **2019**, 134, 2719-2719	2.2	
108	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. *Blood*, **2019**, 134, 5166-5166	2.2	
107	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. *Leukemia and Lymphoma*, **2019**, 60, 1146-1155	1.9	4
106	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. *Blood*, **2019**, 133, 1140-1151	2.2	61
105	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. *Blood*, **2019**, 133, 1457-1464	2.2	79
104	An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. *Leukemia and Lymphoma*, **2019**, 60, 1030-1035	1.9	7
103	CD34CD38 leukemic stem cell frequency to predict outcome in acute myeloid leukemia. *Leukemia*, **2019**, 33, 1102-1112	10.7	74

102	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. *New England Journal of Medicine*, **2018**, 378, 1189-1199	59.2	396
101	Including historical data in the analysis of clinical trials: Is it worth the effort?. *Statistical Methods in Medical Research*, **2018**, 27, 3167-3182	2.3	50
100	Reply to Response to proposal for a novel cancer drug pricing model*Nature Reviews Clinical Oncology*, **2018**, 15, 528-529	19.4	
99	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. *Blood*, **2018**, 132, 1526-1534	2.2	57
98	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. *Blood*, **2018**, 131, 2661-2669	2.2	196
97	Sustainability and affordability of cancer drugs: a novel pricing model. *Nature Reviews Clinical Oncology*, **2018**, 15, 405-406	19.4	36
96	Reply to Economic comments on proposal for a novel cancer drug pricing model*Nature Reviews Clinical Oncology*, **2018**, 15, 588	19.4	1
95	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. *New England Journal of Medicine*, **2018**, 378, 2443	59.2	5
94	Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 CD3 Bispecific Dart Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2018**, 132, 444-444	2.2	9
93	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart Molecule for T-Cell Redirected Therapy. *Blood*, **2018**, 132, 2738-2738	2.2	7
92	Phase 1 Cohort Expansion of Flotetuzumab, a CD123CD3 Bispecific Dart Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood*, **2018**, 132, 764-764	2.2	25
91	Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.. *Journal of Clinical Oncology*, **2018**, 36, 7045-7045	2.2	
90	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. *Blood*, **2018**, 132, 1533-1533	2.2	
89	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. *Blood*, **2017**, 129, 1636-1645	2.2	61
88	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*, **2017**, 129, 424-447	2.2	2764
87	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission.. *JCO Precision Oncology*, **2017**, 1, 1-13	3.6	8
86	Clinical impact of expression in high-risk acute promyelocytic leukemia. *Blood Advances*, **2017**, 1, 1807-1818	7.8	8
85	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. *Blood Advances*, **2017**, 1, 86-89	7.8	78

84	Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2017**, 130, 637-637	2.2	41
83	Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML. *Blood*, **2017**, 130, LBA-5-LBA-5	2.2	10
82	MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. *Blood* , **2016**, 128, 2253-2257	2.2	21
81	The European Cancer Patient Bill of Rights, update and implementation 2016. *ESMO Open*, **2016**, 1, e000127	6	25
80	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. *Nature Medicine*, **2016**, 22, 792-9	50.5	217
79	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. *Blood*, **2016**, 128, 3467-3467	2.2	
78	DNMT3A Mutations Enhance CpG Mutagenesis through Deregulation of the Active DNA Demethylation Pathway. *Blood*, **2016**, 128, 1076-1076	2.2	
77	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. *Haematologica*, **2016**, 101, e284-6	6.6	15
76	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. *Annals of Hematology*, **2015**, 94, 1347-56	3	24
75	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. *Blood*, **2015**, 125, 2985-94	2.2	39
74	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. *Blood*, **2015**, 125, 133-9	2.2	64
73	How I treat the older patient with acute myeloid leukemia. *Blood*, **2015**, 125, 767-74	2.2	143
72	Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. *Blood*, **2015**, 125, 2461-6	2.2	59
71	High Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. *Blood*, **2015**, 126, 2302-6	2.2	22
70	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. *Haematologica*, **2015**, 100, e409-11	6.6	9
69	Dick W. van Bekkum, 1925-2015. *Transplantation*, **2015**, 99, 2442-3	1.8	
68	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. *Blood*, **2015**, 126, 2547-2547	2.2	40
67	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. *Blood*, **2015**, 126, 306-306	2.2	2

66	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. *Annals of Hematology*, **2014**, 93, 2001-10	3	40
65	A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. *Cell*, **2014**, 157, 369-381	56.2	419
64	Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. *British Journal of Haematology*, **2014**, 166, 540-9	4.5	10
63	Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. *PLoS ONE*, **2014**, 9, e107587	3.7	127
62	Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage. *Blood*, **2014**, 124, 1067-1067	2.2	
61	Defects in the RAS/RTK Signaling Pathways Predominate the Mutational Spectrum of EVI1/GATA2 Rearranged Myeloid Malignancies with Inv(3)/t(3;3). *Blood*, **2014**, 124, 701-701	2.2	
60	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. *Blood*, **2014**, 124, 3676-3676	2.2	
59	Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. *Blood*, **2013**, 121, 26-8	2.2	113
58	A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. *Experimental Hematology and Oncology*, **2013**, 2, 7	7.8	8
57	High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *Journal of Clinical Oncology*, **2013**, 31, 3889-97	2.2	301
56	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. *Blood*, **2013**, 121, 1935-43	2.2	77
55	Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 2516-2516	2.2	
54	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2013**, 122, 303-303	2.2	
53	PU.1 Is Essential For MLL Leukemia Via Activation Of The Meis/HOX Pathway and A Monocytic Cytokine Mediated Anti-Apoptotic Inflammatory Program. *Blood*, **2013**, 122, 1276-1276	2.2	
52	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. *Blood*, **2013**, 122, 64-64	2.2	1
51	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. *Blood*, **2013**, 122, 2586-2586	2.2	
50	Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. *Blood*, **2012**, 119, 5367-73	2.2	73
49	miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. *Nature Communications*, **2012**, 3, 688	17.4	121

48	The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia. *Blood*, **2012**, 120, 3522-3522	2.2	
47	The Gene Encoding Nuclear Erythroid Factor 2 (NFE2) Is Recurrently Mutated in Acute Myeloid Leukemia. *Blood*, **2012**, 120, 1392-1392	2.2	
46	BAALC and EVI1 Prognostic Gene Expression in Adult Acute Myeloid Leukemia Using the Amlprofiler Custom Microarray. *Blood*, **2012**, 120, 1420-1420	2.2	
45	Prognostic and Functional Relevance of Aberrant Microrna-9/9* Expression in Acute Myeloid Leukemia.. *Blood*, **2012**, 120, 2542-2542	2.2	
44	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. *Haematologica*, **2011**, 96, 1470-7	6.6	48
43	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. *Blood*, **2011**, 117, 1799-805	2.2	95
42	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. *Blood*, **2011**, 117, 4561-8	2.2	81
41	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. *Blood*, **2011**, 118, 6030-6	2.2	85
40	Cytarabine dose for acute myeloid leukemia. *New England Journal of Medicine*, **2011**, 364, 1027-36	59.2	277
39	Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab. *Blood*, **2011**, 118, 1555-1555	2.2	1
38	The Growth Factor Independence 1 variant form GFI136N Predisposes to Acute Myeloid Leukemia by Inducing Epigenetic Changes in Oncogenes Such As Hoxa9. *Blood*, **2011**, 118, 223-223	2.2	3
37	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. *Blood*, **2011**, 118, 3552-3552	2.2	
36	Np73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,. *Blood*, **2011**, 118, 3536-3536	2.2	
35	Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML. *Blood*, **2011**, 118, 2030-2030	2.2	
34	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning. *Blood*, **2011**, 118, 159-159	2.2	1
33	A Single Microarray Assay for Simultaneous Diagnosis of t(15;17), t(8;21), Inv(16)/t(16;16), NPM1 Type A/B/D Mutation, CEBPA Double Mutation, and Aberrant Expression of BAALC or EVI1 in AML/APL Patients. *Blood*, **2011**, 118, 4876-4876	2.2	
32	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. *Blood*, **2011**, 118, 236-236	2.2	
31	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. *Blood*, **2011**, 118, 1441-1441	2.2	

30	Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. *Journal of Clinical Oncology*, **2010**, 28, 4333-8	2.2	56
29	Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. *Blood*, **2010**, 115, 2586-91	2.2	114
28	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. *Blood*, **2010**, 115, 5137-46	2.2	234
27	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. *Haematologica*, **2010**, 95, 424-31	6.6	72
26	DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer Cell*, **2010**, 17, 13-27	24.3	640
25	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*, **2010**, 18, 553-67	24.3	1933
24	High Prognostic Impact of Mixed Chimerism of Blood and Marrow In the First Year After Allogeneic Hematopoietic Stem Cell Transplantation: The Need to Rapidly Establish Complete Donor Chimerism.. *Blood*, **2010**, 116, 3464-3464	2.2	
23	CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies. *Blood*, **2010**, 116, 3279-3279	2.2	
22	High-dose daunorubicin in older patients with acute myeloid leukemia. *New England Journal of Medicine*, **2009**, 361, 1235-48	59.2	622
21	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*, **2009**, 113, 1875-91	2.2	720
20	Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 2080-2080	2.2	5
19	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. *Blood*, **2009**, 114, 6-6	2.2	7
18	VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.. *Blood*, **2009**, 114, 997-997	2.2	1
17	DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 707-707	2.2	
16	Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.. *Blood*, **2009**, 114, 1062-1062	2.2	
15	Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *Journal of Clinical Oncology*, **2008**, 26, 4791-7	2.2	453
14	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. *Blood*, **2008**, 112, 3130-4	2.2	129
13	Acute myeloid leukemia: the challenge of capturing disease variety. *Hematology American Society of Hematology Education Program*, **2008**, 1-11	3.1	74

12	Double, but Not Single, CEBPA mutations Define a Subgroup of Acute Myeloid Leukemia with Favorable Outcome and a Distinct Gene Expression Profile. *Blood*, **2008**, 112, 141-141	2.2	1
11	Genetic vs. Epigenetic Disruption of the CEBPA Locus Yields Epigenomically and Biologically Distinct Leukemia Phenotypes.. *Blood*, **2007**, 110, 2117-2117	2.2	1
10	A Two-Gene Classifier for Predicting Response to the Farnesyltransferase Inhibitor Tipifarnib in Acute Myeloid Leukemia.. *Blood*, **2007**, 110, 1445-1445	2.2	
9	High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.. *Blood*, **2007**, 110, 4297-4297	2.2	0
8	Prognostically useful gene-expression profiles in acute myeloid leukemia. *New England Journal of Medicine*, **2004**, 350, 1617-28	59.2	1106
7	A Novel Subgroup of Poor Prognostic AML with Low CEBPA Expression, CEBPA Promoter Hypermethylation and DNMT3b Overexpression.. *Blood*, **2004**, 104, 418-418	2.2	1
6	Clinical Useful Prognostic Index for Adult Patients with Acute Myeloid Leukemia in First Relapse.. *Blood*, **2004**, 104, 2011-2011	2.2	
5	Acceleration and Enhancement of T-Cell Recovery and Immune Competence by Flt3-Ligand (Flt3L) Following BMT with Low Numbers of Progenitor Cells in Immune Deficient Mice.. *Blood*, **2004**, 104, 47-47	2.2	
4	Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. *New England Journal of Medicine*, **2003**, 349, 743-52	59.2	326
3	Minimal residual disease in chronic myeloid leukemia. *New England Journal of Medicine*, **2003**, 349, 1399-401	59.2	51
2	Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2003**, 21, 4642-9	2.2	2107
1	Acute myeloid leukemia and acute promyelocytic leukemia. *Hematology American Society of Hematology Education Program*, **2003**, 82-101	3.1	26